Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) EBIT (2016 - 2025)

Rockwell Medical (RMTI) has disclosed EBIT for 16 consecutive years, with -$1.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 181.82% year-over-year to -$1.6 million, compared with a TTM value of -$4.8 million through Sep 2025, down 929.66%, and an annual FY2024 reading of $608000.0, up 109.12% over the prior year.
  • EBIT was -$1.6 million for Q3 2025 at Rockwell Medical, down from -$1.3 million in the prior quarter.
  • Across five years, EBIT topped out at $1.9 million in Q3 2024 and bottomed at -$8.4 million in Q4 2021.
  • Average EBIT over 5 years is -$3.0 million, with a median of -$1.7 million recorded in 2023.
  • The sharpest move saw EBIT surged 211.46% in 2024, then tumbled 361.94% in 2025.
  • Year by year, EBIT stood at -$8.4 million in 2021, then soared by 76.5% to -$2.0 million in 2022, then soared by 72.15% to -$547000.0 in 2023, then rose by 5.12% to -$519000.0 in 2024, then plummeted by 205.2% to -$1.6 million in 2025.
  • Business Quant data shows EBIT for RMTI at -$1.6 million in Q3 2025, -$1.3 million in Q2 2025, and -$1.4 million in Q1 2025.